Accueil>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Zidebactam

Zidebactam (Synonyms: WCK-5107)

Catalog No.GC34870

Le zidebactam (WCK-5107) est un puissant inhibiteur de la β-lactamase.

Products are for research use only. Not for human use. We do not sell to patients.

Zidebactam Chemical Structure

Cas No.: 1436861-97-0

Taille Prix Stock Qté
10mM (in 1mL DMSO)
228,00 $US
En stock
5mg
207,00 $US
En stock
10mg
342,00 $US
En stock
50mg
1 125,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Zidebactam (WCK-5107) is a potent β-lactamase inhibitor[1]. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL[2]. IC50: 0.26 μg/mL (P. aeruginosa PAO1 PBP2)[2]

Zidebactam (WCK-5107) inhibits WT Enterobacteriaceae with a MIC50 of 0.25 mg/L. Zidebactam alone exhibits variable activity when tested against E. coli (MIC50/90 0.12/0.12 mg/L) and Enterobacter spp. (MIC50/90 0.12/0.25 mg/L)[1].

[1]. Sader HS, et al. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. [2]. Moya B, et al. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017 May 24;61(6).

Avis

Review for Zidebactam

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Zidebactam

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.